Imbio PHA (4.0.0) vs DeepTek CXR Analyzer
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is automated, precise measurement of cardiac structures from CT pulmonary angiogram (CTPA) scans. This tool is ideal for assessing right ventricular dilation and aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension, providing specific RV/LV and PA/Ao ratios.
View Imbio PHA (4.0.0) →Choose DeepTek CXR Analyzer if…
Choose DeepTek CXR Analyzer if you require an AI-powered solution for comprehensive, initial screening and detection of a wide range of pathologies on chest X-rays. This tool is best suited for improving radiologist workflow efficiency and diagnostic accuracy by automatically highlighting suspicious regions across lung, pleural, and cardiac findings.
View DeepTek CXR Analyzer →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | DeepTek CXR Analyzer |
|---|---|---|
| Pricing | Unknown | Global access pricing available for eligible public sector and not-for-profit healthcare providers in 138 low- and middle-income countries, offering unlimited ai analyses per connected x-ray unit, installation, user training, product updates, maintenance, and technical support via an annual subscription. |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | On-premise and Cloud offerings. The solution supports online, offline, and hybrid deployment. |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
DeepTek CXR AnalyzerDeepTek CXR Analyzer (Tool B) explicitly highlights features that directly enhance radiologist workflow, such as 'Intelligent segregation of scans into 'AI Finding-Negative' and 'AI Finding-Positive'' and claims to 'Reduces radiologist workload by 30-50% and boosts productivity by 2x-3x'. While Imbio PHA (Tool A) offers rapid, automated assessment and DICOM integration, Tool B's stated impact on workload and productivity indicates a stronger focus on practical usability for radiologists.
Clinical Value
Imbio PHA (4.0.0)Both tools are FDA-cleared, indicating clinical validation. Imbio PHA (Tool A) provides automated, quantitative measurements of cardiac structures from CTPA scans to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. This focus on precise, quantitative metrics for critical and complex conditions offers a high clinical value for specific diagnostic and risk assessment pathways. DeepTek CXR Analyzer (Tool B) offers broad detection of 28 findings on chest X-rays, which is valuable for general screening and workflow, but Tool A's specialized quantitative output for high-stakes conditions provides a distinct clinical advantage in its niche.
Pricing & Value
DeepTek CXR AnalyzerDeepTek CXR Analyzer (Tool B) offers a 'Pay-per-use' pricing model, which provides transparency and flexibility, allowing healthcare providers to align costs with actual utilization. Imbio PHA (Tool A) only states 'contact for pricing,' offering no immediate insight into its cost structure. The clear and flexible pricing model of Tool B provides better perceived value and financial predictability for potential customers.
Enterprise Readiness
Imbio PHA (4.0.0)Both tools offer cloud and on-premise deployment options, are HIPAA compliant, and FDA cleared. However, Imbio PHA (Tool A) explicitly states its HIPAA compliance is 'third-party certified by compliancy group' and mentions deployment 'via partners,' suggesting a more robust and flexible integration strategy for diverse enterprise environments. These details indicate a slightly more mature and validated approach to enterprise deployment and compliance.
Innovation
Imbio PHA (4.0.0)Both tools leverage AI for medical imaging analysis. Imbio PHA (Tool A) demonstrates innovation through its precise, automated quantitative measurements of cardiac structures from CTPA, specifically for aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension. This specialized quantitative analysis for complex, high-stakes conditions represents a significant advancement in diagnostic capabilities. While DeepTek CXR Analyzer (Tool B) offers broad detection of 28 pathologies on chest X-rays, Tool A's depth in quantitative biomarker analysis for critical conditions gives it a slight edge in specialized innovation.
Support & Docs
Imbio PHA (4.0.0)Imbio (Tool A) explicitly states that it offers '24/7/365 support for all our customers worldwide', providing a clear commitment to continuous availability for assistance. While DeepTek (Tool B) provides contact information for support via email and phone, it does not specify the same level of round-the-clock availability. Imbio also indicates that user manuals and product documentation are available upon request, and provides FAQs online.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | DeepTek CXR Analyzer |
|---|---|---|
| Tool Name | Imbio PHA (4.0.0) | DeepTek CXR Analyzer |
| Company | Imbio | DeepTek Medical Imaging Pvt |
| Primary Imaging Modality | CT pulmonary angiogram (CTPA) scans | Chest X-ray |
| Key Functionality | Automated measurement of cardiac structures (RV/LV, PA/Ao diameters and ratios) for pulmonary embolism and hypertension assessment | AI-Powered Computer-Assisted Detection (CADe) for 28 findings across lung, pleural, and cardiac pathologies |
| Output Format | Annotated DICOM images, PDF summary reports | Secondary capture DICOM with AI output |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and DeepTek CXR Analyzer.